Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab +/- High Dose Interferon-Alpha in Advanced Melanoma
NCT01708941Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2013
- Primary completion
- Aug 2017
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and interferon alfa-2b in melanoma (4 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival. Started Mar 2013; status: completed.
02
Drugs
ipilimumabinterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01708941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01708941.